

Jenny Han

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11990333/publications.pdf>

Version: 2024-02-01

27
papers

4,121
citations

471477

17
h-index

526264

27
g-index

27
all docs

27
docs citations

27
times ranked

3295
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of Exenatide (Exendin-4) on Glycemic Control and Weight Over 30 Weeks in Metformin-Treated Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2005, 28, 1092-1100.	8.6	1,390
2	Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2004, 27, 2628-2635.	8.6	1,196
3	Identification of a Novel Macrophage Phenotype That Develops in Response to Atherogenic Phospholipids via Nrf2. <i>Circulation Research</i> , 2010, 107, 737-746.	4.5	472
4	Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review. <i>Clinical Therapeutics</i> , 2012, 34, 1247-1258.e22.	2.5	229
5	Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 464-473.	11.4	138
6	Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2011, 10, 22.	6.8	137
7	Efficacy, Safety, and Tolerability of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus: An Integrated Analysis of the DURATION Trials. <i>Postgraduate Medicine</i> , 2013, 125, 47-57.	2.0	68
8	Disabled homolog 2 controls macrophage phenotypic polarization and adipose tissue inflammation. <i>Journal of Clinical Investigation</i> , 2016, 126, 1311-1322.	8.2	68
9	Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years. <i>BMC Endocrine Disorders</i> , 2011, 11, 9.	2.2	61
10	Upper and/or lower gastrointestinal adverse events with glucagon-like peptide-1 receptor agonists: incidence and consequences. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 672-681.	4.4	53
11	Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 393-403.	4.4	53
12	Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2012, 5, 29.	2.4	38
13	Efficacy and Tolerability of Exenatide Once Weekly Over 6 Years in Patients with Type 2 Diabetes: An Uncontrolled Open-Label Extension of the DURATION-1 Study. <i>Diabetes Technology and Therapeutics</i> , 2016, 18, 677-686.	4.4	38
14	Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QT c interval in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 979-989.	2.4	31
15	Exenatide is Non-inferior to Insulin in Reducing HbA _{1c} : An Integrated Analysis of 1423 Patients with Type 2 Diabetes. <i>Postgraduate Medicine</i> , 2010, 122, 118-128.	2.0	28
16	Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis. <i>Vascular Health and Risk Management</i> , 2012, 8, 255.	2.3	21
17	Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals. <i>Cardiovascular Diabetology</i> , 2013, 12, 48.	6.8	20
18	Efficacy and tolerability of exenatide once weekly over 7 years in patients with type 2 diabetes: An open-label extension of the DURATION-1 study. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 223-230.	2.3	17

#	ARTICLE	IF	CITATIONS
19	Exenatide versus Insulin Lispro Added to Basal Insulin in a Subgroup of Korean Patients with Type 2 Diabetes Mellitus. <i>Diabetes and Metabolism Journal</i> , 2017, 41, 69.	4.7	12
20	Addition of exenatide BID to insulin glargine: a post-hoc analysis of the effect on glycemia and weight across a range of insulin titration. <i>Current Medical Research and Opinion</i> , 2014, 30, 1209-1218.	1.9	8
21	Early Pharmacodynamic Effects of Exenatide Once Weekly in Type 2 Diabetes Are Independent of Weight Loss: A Pooled Analysis of Patient-level Data. <i>Clinical Therapeutics</i> , 2016, 38, 1464-1473.	2.5	8
22	Efficacy and Tolerability of Exenatide Once Weekly Versus Sitagliptin in Patients With Type 2 Diabetes Mellitus: A Retrospective Analysis of Pooled Clinical Trial Data. <i>Postgraduate Medicine</i> , 2013, 125, 58-67.	2.0	7
23	Three-year efficacy and safety of exenatide once weekly: A pooled analysis of three trials. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 1415-1422.	2.3	7
24	Changes in Heart Rate Associated with Exenatide Once Weekly: Pooled Analysis of Clinical Data in Patients with Type 2 Diabetes. <i>Diabetes Therapy</i> , 2018, 9, 551-564.	2.5	7
25	Variability in and predictors of glycaemic responses after 24 weeks of treatment with exenatide twice daily and exenatide once weekly. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1793-1797.	4.4	7
26	Effects of exenatide twice daily, exenatide once weekly or insulin in patients with type 2 diabetes and baseline HbA1c $\geq 10.0\%$: Two pooled analyses including 20 randomised controlled trials. <i>International Journal of Clinical Practice</i> , 2017, 71, e13029.	1.7	4
27	Long-Term Effects of Adding Exenatide to a Regimen of Metformin and/or Sulfonylurea in Type 2 Diabetes: An Uncontrolled, Open-Label Trial in Hungary. <i>Clinical Therapeutics</i> , 2012, 34, 1301-1313.	2.5	3